Xcout Intel
Bantam Pharmaceutical, LLC
Bantam Pharmaceutical, LLC is a clinical-stage biopharmaceutical company that develops novel, first-in-class small molecule oral therapeutics for oncology. The company targets mitochondrial dynamics to restore apoptosis in cancer cells, with a lead candidate focused on treating difficult hematological and solid tumors such as Diffuse Large B-cell Lymphoma.
Subscribe to see Bantam Pharmaceutical, LLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Bantam Pharmaceutical, LLC at a glance
Bantam Pharmaceutical, LLC is a biotechnology company headquartered in United States. It has raised at least $32M across the 2 funding rounds on record. Its most recent funding round, Seed, raised $25M in September 2021. Xcout tracks 10 named people at Bantam Pharmaceutical, LLC, including MICHAEL STOCUM (PRESIDENT CEO).
Bantam Pharmaceutical, LLC leadership
- MICHAEL STOCUMPRESIDENT CEO
- Glen WeissCHIEF MEDICAL OFFICER
- Matthew KosturaCHIEF SCIENTIFIC OFFICER
- Michael LutherFounding CEO, Bantam Pharmaceutical CEO STRM.BIO Former Astellas, Merck GSK
- Meghan ReynoldsCHIEF OF STAFF
- Andy AnanthaHEAD OF CMC
4 more named people on record for Bantam Pharmaceutical, LLC, with roles, board committees and tenure — see the full roster →
Bantam Pharmaceutical, LLC funding rounds
At least $32M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $25M | — | |
| SEC Form D filing | $7M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Bantam Pharmaceutical, LLC competitors
A few of Bantam Pharmaceutical, LLC's closest competitors — see the full list of competitors and alternatives →
Bio-Path Holdings, Inc. is a U.S.-based pharmaceutical company focused on developing RNAi nanoparticle drugs for oncology, with programs spanning both clinical and preclinical stages. Its innovative product development is centered around the DNAbilize platform, a drug delivery and antisense technology that employs a P-ethoxy modified deoxyribonucleic acid (DNA) backbone. This modification is specifically engineered to shield the DNA from premature degradation. The company's lead drug candidate, prexigebersen, is presently in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. Additionally, Bio-Path is advancing Liposomal Bcl-2 for refractory/relapsed lymphoma and chronic lymphocytic leukemia. Another promising asset, Liposomal STAT3, is in preclinical development, targeting pancreatic cancer, non-small cell lung cancer, and AML. Furthermore, prexigebersen-A is under development for various solid tumors. Bio-Path Holdings, Inc., founded in 2007, is headquartered in Bellaire, Texas.
Pretzel Therapeutics is a biotechnology company headquartered in Boston, Massachusetts, advancing a new class of medicines that target cellular energetics and mitochondrial function.
Oxford BioTherapeutics is a clinical-stage oncology company focused on developing first-in-class cancer therapeutics with a proprietary pipeline. The company operates from locations in Oxford, United Kingdom, as well as San Jose, California, and Morristown, New Jersey, in the United States.
ImmPACT Bio is a biotechnology company developing next-generation cancer immunotherapies, including dual-targeted CAR T-cell therapies. Its programs are intended to serve patients with B-cell malignancies and potentially other cancers, including solid tumors.
Bellicum Pharmaceuticals, Inc. is a company focused on engineering high-performance cellular immunotherapies. These therapies are developed to combat diseases.
Whitehawk Therapeutics Inc. is a biopharmaceutical enterprise currently undergoing clinical trials. This company specializes in crafting highly targeted treatment options for cancers that are identified by distinct genetic profiles.
Get Bantam Pharmaceutical, LLC's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Bantam Pharmaceutical, LLC in Xcout Intel
- 10 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access